PMID- 22471811
OWN - NLM
STAT- MEDLINE
DCOM- 20130117
LR  - 20151119
IS  - 1751-553X (Electronic)
IS  - 1751-5521 (Linking)
VI  - 34
IP  - 4
DP  - 2012 Aug
TI  - Light chain deposition disease: novel biological insights and treatment advances.
PG  - 347-55
LID - 10.1111/j.1751-553X.2012.01419.x [doi]
AB  - Light chain deposition disease (LCDD) is a monoclonal gammopathy characterized by 
      nonamyloid deposition of immunoglobulin light chains in various organs. Most 
      cases present with renal dysfunction, a ubiquitous feature of this disease, and 
      in some instances, it may progress to end-stage renal disease. Unfortunately, 
      until now, no standard treatment has been established. The use of alkylating 
      agents and steroids has been extensively reported. However, conventional 
      chemotherapy response is generally limited with minor effects on kidney function. 
      The use of novel agents such as bortezomib has shown a more rapid response with a 
      dramatically important reduction of light chains in serum and/or urine in small 
      series of cases. Furthermore, autologous stem cell transplantation has been 
      reported as a feasible strategy in LCDD, able to prolong the dialysis-free 
      survival. Nonetheless, toxicity from these therapies should be considered 
      carefully because most of patients might present with kidney dysfunction that 
      could limit the use of some agents.
CI  - (c) 2012 Blackwell Publishing Ltd.
FAU - Jimenez-Zepeda, V H
AU  - Jimenez-Zepeda VH
AD  - Department of Medical Oncology and Hematology, Princess Margaret Hospital, 
      Toronto, ON, Canada. victor.zepeda@uhn.ca
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20120404
PL  - England
TA  - Int J Lab Hematol
JT  - International journal of laboratory hematology
JID - 101300213
RN  - 0 (Boronic Acids)
RN  - 0 (Immunoglobulin Light Chains)
RN  - 0 (Pyrazines)
RN  - 69G8BD63PP (Bortezomib)
SB  - IM
MH  - Boronic Acids/therapeutic use
MH  - Bortezomib
MH  - Female
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Immunoglobulin Light Chains/*metabolism
MH  - Kidney Failure, Chronic/complications/drug therapy/*physiopathology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Multiple Organ Failure/complications/drug therapy/*physiopathology/*therapy
MH  - Pyrazines/therapeutic use
EDAT- 2012/04/05 06:00
MHDA- 2013/01/18 06:00
CRDT- 2012/04/05 06:00
PHST- 2012/04/05 06:00 [entrez]
PHST- 2012/04/05 06:00 [pubmed]
PHST- 2013/01/18 06:00 [medline]
AID - 10.1111/j.1751-553X.2012.01419.x [doi]
PST - ppublish
SO  - Int J Lab Hematol. 2012 Aug;34(4):347-55. doi: 10.1111/j.1751-553X.2012.01419.x. 
      Epub 2012 Apr 4.